CRIXIVAN
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Mar 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CRIXIVAN (indinavir) is an oral HIV-1 protease inhibitor approved in 1996 by Merck & Co. It binds to the HIV-1 protease active site and prevents cleavage of viral polyproteins, resulting in the formation of immature, non-infectious viral particles. The drug is indicated for treatment of HIV infection.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), indicating a maturing market with shrinking team investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
200 enrolled
HIV Infections
Career Relevance
Working on CRIXIVAN represents a late-career opportunity in lifecycle management and market defense rather than growth and innovation. Professionals on this brand should expect focus on cost containment, patient retention, and potential transition planning as LOE approaches.
Brand Manager
Worked on CRIXIVAN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.